In cutaneous squamous cell carcinoma (SCC), AXL contributes to cell invasiveness and stemness by modulating Wnt and TGF-β signaling pathways and disrupting cell-to-cell adhesion.103 Furthermore, suppressing AXL through inhibitors or shRNA extends the survival of chronic myeloid leukemia (CML) mice and reduces the growth of leukemia stem cells (LSCs). Here, AXL is linked to chronic myelogenous leukemia, BCR-ABL1 positive.